Laboratory Corporation of America Holdings Stock price

Equities

LH

US50540R4092

Healthcare Facilities & Services

Market Closed - Nyse 04:00:02 2024-03-18 pm EDT 5-day change 1st Jan Change
209.5 USD +0.16% Intraday chart for Laboratory Corporation of America Holdings -4.11% -7.81%
Sales 2024 * 12.76B Sales 2025 * 13.29B Capitalization 17.62B
Net income 2024 * 1B Net income 2025 * 1.13B EV / Sales 2024 * 1.72 x
Net Debt 2024 * 4.35B Net Debt 2025 * 3.86B EV / Sales 2025 * 1.62 x
P/E ratio 2024 *
17.8 x
P/E ratio 2025 *
15.8 x
Employees 61,975
Yield 2024 *
1.42%
Yield 2025 *
1.46%
Free-Float 98.76%
More Fundamentals * Assessed data
Dynamic Chart
Laboratory Corp Of America Holdings Insider Sold Shares Worth $1,102,736, According to a Recent SEC Filing MT
Labcorp Launches Weight Loss Management Testing Solutions CI
Pinnacle Fertility Partners with Labcorp to Advance Genetic Testing Services CI
Leerink Partners Initiates Coverage on Laboratory Corp of America With Outperform Rating, $260 Price Target MT
Laboratory Corp Of America Holdings Insider Sold Shares Worth $7,451,866, According to a Recent SEC Filing MT
Deutsche Bank Raises Laboratory Corp of America Price Target to $220 From $215, Maintains Hold Rating MT
Laboratory Corporation of America Holdings to Seek Acquisitions CI
Transcript : Laboratory Corporation of America Holdings, Q4 2023 Earnings Call, Feb 15, 2024
Laboratory Corp of America Holdings' Q4 Adjusted Earnings, Revenue Rise; 2024 Adjusted Earnings Outlook Issued MT
Tranche Update on Laboratory Corporation of America Holdings (NYSE:LH)'s Equity Buyback Plan announced on December 9, 2021. CI
Laboratory Corporation of America Holdings Announces Quarterly Cash Dividend, Payable on March 13, 2024 CI
Earnings Flash (LH) LABORATORY CORPORATION OF AMERICA HOLDINGS Posts Q4 Revenue $3.03B, vs. Street Est of $3.02B MT
Earnings Flash (LH) LABORATORY CORPORATION OF AMERICA HOLDINGS Posts Q4 EPS $3.30, vs. Street Est of $3.26 MT
Laboratory Corporation of America Holdings Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Tech-led U.S. 'exceptionalism' underlined RE
More news

Latest transcript on Laboratory Corporation of America Holdings

1 day+0.16%
1 week-3.66%
Current month-2.91%
1 month-3.28%
3 months-4.54%
6 months+3.91%
Current year-7.81%
More quotes
1 week
206.37
Extreme 206.37
218.51
1 month
206.37
Extreme 206.37
221.14
Current year
206.37
Extreme 206.37
234.09
1 year
195.01
Extreme 195.01
243.30
3 years
195.01
Extreme 195.01
317.17
5 years
98.02
Extreme 98.02
317.17
10 years
93.46
Extreme 93.46
317.17
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 13-03-31
Director of Finance/CFO 62 14-06-15
Compliance Officer 65 19-01-31
Members of the board TitleAgeSince
Director/Board Member 75 07-05-15
Chief Executive Officer 59 13-03-31
Director/Board Member 74 95-04-27
More insiders
Date Price Change Volume
24-03-18 209.5 +0.16% 877,597
24-03-15 209.2 +0.10% 1,388,743
24-03-14 209 -3.12% 1,582,566
24-03-13 215.8 -0.51% 541,043
24-03-12 216.9 -0.76% 395,554

Delayed Quote Nyse, March 18, 2024 at 04:00 pm EDT

More quotes
Laboratory Corporation of America Holdings is the No. 2 clinical laboratory in the United States. Net sales (including intragroup) break down by activity as follows: - clinical laboratory services (63.9%): routine testing, patient diagnosis, disease monitoring and treatment, and other services; - development and clinical trial services (36.1%): for pharmaceutical, biotechnology, medical device and diagnostic companies. Net sales are distributed geographically as follows : North America (81.2%), Europe (12.7%) and other (6.1%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
209.5 USD
Average target price
244.9 USD
Spread / Average Target
+16.86%
Consensus
  1. Stock
  2. Equities
  3. Stock Laboratory Corporation of America Holdings - Nyse